Media Room

Agilent at AACR 2024 

Agilent highlighted scientific innovations in the areas of cancer research, integrated workflows, companion diagnostics, digital/spatial pathology, and Agilent’s evolving cancer strategy at the American Association for Cancer Research (AACR) Annual Meeting 2024, held April 5 - 10, 2024 in San Diego, California.

Agilent at AACR 2024

Advancing Breakthroughs in Cancer Research

Advances in cell analysis, genomics, metabolic studies, protein profiling, and pathology are revealing new connections in our understanding of cancer and a comprehensive picture. From new understandings of tumor genomic microheterogeneity, to powerful and precise therapies such as immune checkpoint inhibitors. It’s an exciting time to be researching breakthroughs that could affect many lives.  Whether your early discovery research, clinical trials or diagnostic tools development, Agilent is there to support scientists with an integrated portfolio of solutions. 

 


Next Generation Solutions Featured at AACR 2024

    • Agilent NovoCyte Opteon Spectral Flow Cytometer

      The Agilent NovoCyte Opteon Spectral Flow Cytometer, is an advanced solution in spectral flow cytometry. This user-friendly system allows simultaneous analysis of multiple markers and offers flexibility in designing multiple marker panels. With configurations ranging from 3 to 5 lasers and support for up to 70 high-quality detectors, the NovoCyte Opteon promises enhanced research capabilities for scientists and researchers.

    • Agilent Avida

      Agilent Avida's new cutting-edge target enrichment solutions enable simultaneous DNA and methylation profiling from a single sample. The proprietary Avida technology maintains original sample quality and quantity, supporting advanced applications such as liquid biopsy and multiomics capabilities for targeted next-generation sequencing (NGS). Researchers gain accelerated access to genetic and epigenetic data from limited samples, propelling cancer biology and clinical insights. The high-performance and streamlined workflows offer outstanding fidelity, turnaround time, and ease of use.

    • Agilent SureSelect Cancer Custom panels

      Agilent SureSelect Cancer Custom panels offer the ability to add new and emerging biomarkers, including tumor mutational burden (TMB) and microsatellite instability (MSI), to custom tumor genomic profiling assays. These custom NGS cancer panels are designed quickly and easily using Agilent SureDesign 8.0, an intuitive probe design software powered by machine learning. These custom cancer panels extend the SureSelect Cancer product portfolio and underscore Agilent’s commitment to advancing precision oncology.

    • Agilent SureSelect CD CiberMed Tissue and SureSelect CD CiberMed Heme panels

      Agilent announces a new partnership with CiberMed. This company aims to simplify cellular profiling and biomarker discovery with its digital cytometry software, iSort. The new Agilent SureSelect CD CiberMed Tissue and SureSelect CD CiberMed Heme panels enable a combined SureSelect and iSort workflow to offer a cellular profiling solution from bulk RNA-Seq data with enhanced sensitivity, accuracy, and robustness.
      - URL coming soon

Agilent Cancer Research Solutions

    • Cell Analysis

      Investigate dynamic cancer cell strategies with innovative cell analysis technologies.

    • Genomics

      Agilent’s cancer genomic research solutions provide accurate data, insights, and enhanced productivity while improving your ability to deliver trusted answers to your critical challenges.

    • Biomarkers

      Precision medicine has created a need for new cancer biomarkers for sample stratification, compound response, biobanked tissue, and disease understanding.

    • Diagnostics

      Agilent builds on 50+ years of experience and cutting-edge diagnostic research to ensure a precisely calibrated assay for each companion therapy.

    • Companion Diagnostics

      Agilent's pharmDx solution is a portfolio of all-in-one pharmDx kits that lead to optimal diagnostic results within companion diagnostics.

    • Biologics

      Improve efficiency and increase confidence in biopharmaceutical discovery and development.